Compare VVV & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VVV | VRDN |
|---|---|---|
| Founded | 1866 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Medical Specialities |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9B | 3.2B |
| IPO Year | 2016 | N/A |
| Metric | VVV | VRDN |
|---|---|---|
| Price | $38.56 | $27.81 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 15 | 13 |
| Target Price | $39.53 | ★ $41.42 |
| AVG Volume (30 Days) | ★ 2.5M | 1.4M |
| Earning Date | 02-04-2026 | 02-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.67 | N/A |
| Revenue | ★ $1,757,800,000.00 | $70,789,000.00 |
| Revenue This Year | $20.45 | $26,080.80 |
| Revenue Next Year | $10.34 | $2.07 |
| P/E Ratio | $55.92 | ★ N/A |
| Revenue Growth | 5.90 | ★ 23340.07 |
| 52 Week Low | $28.50 | $9.90 |
| 52 Week High | $41.33 | $34.29 |
| Indicator | VVV | VRDN |
|---|---|---|
| Relative Strength Index (RSI) | 71.92 | 34.99 |
| Support Level | $37.60 | $28.44 |
| Resistance Level | $39.42 | $30.50 |
| Average True Range (ATR) | 1.03 | 1.47 |
| MACD | 0.40 | -0.41 |
| Stochastic Oscillator | 83.40 | 7.29 |
Valvoline Inc provides automotive preventive maintenance through retail stores across the U.S. and Canada, offering approximately 15-minute stay-in-your-car oil changes, battery, bulb, and wiper replacements, tire rotations, and other manufacturer-recommended maintenance. Its full-service oil changes include Valvoline oil, a new oil filter, chassis lubrication, and an 18-point maintenance check. The Company provides differential fluid, fuel system cleaning, headlight and taillight replacement, radiator service, transmission service, air conditioning, and air filter replacement. It operates and franchises approximately 2,200 Valvoline Instant Oil Change and Valvoline Great Canadian Oil Change retail locations. The majority of revenue is generated from the United States of America.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).